MedPath

Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension

Phase 3
Conditions
Pulmonary Hypertension
Interventions
Registration Number
NCT01091012
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Brief Summary

The main objective is to validate the safety and efficacy of intravenous and oral sildenafil in the acute vasodilator test in patients with persistence of, at least, moderate pulmonary hypertension after valvular surgery successfully, with a correct left ventricular function and no valvular disease hemodynamically significant.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Patients clinically stable, at least 1 year after the completion of successful valve surgery, with persistent pulmonary artery systolic pressure> 50 mmHg,
  • normal left ventricular function and no significant valvular disease in 2 separate Doppler ultrasound studies at least 1 month.
Exclusion Criteria
  • Patients with other cardiac and noncardiac diseases will be excluded.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sildenafil 10mg intravenousSildenafil 20mg oral vs Sildenafil 10mg intravenous-
Sildenafil 20mg oralSildenafil 20mg oral vs Sildenafil 10mg intravenous-
Primary Outcome Measures
NameTimeMethod
Effectivenessone day per patient

The main efficacy parameter is the effect on pulmonary vascular vasodilation quantified as decreased Pulmonary Vascular Resistance.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Vall Hebron Hospital

🇪🇸

Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath